Nothing Special   »   [go: up one dir, main page]

MX2022014741A - Metodos para detectar bordetella. - Google Patents

Metodos para detectar bordetella.

Info

Publication number
MX2022014741A
MX2022014741A MX2022014741A MX2022014741A MX2022014741A MX 2022014741 A MX2022014741 A MX 2022014741A MX 2022014741 A MX2022014741 A MX 2022014741A MX 2022014741 A MX2022014741 A MX 2022014741A MX 2022014741 A MX2022014741 A MX 2022014741A
Authority
MX
Mexico
Prior art keywords
bordetella
methods
detecting
pertussis
holmesii
Prior art date
Application number
MX2022014741A
Other languages
English (en)
Inventor
Michelle Tabb
Jules Chen
Original Assignee
Quest Diagnostics Invest Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quest Diagnostics Invest Llc filed Critical Quest Diagnostics Invest Llc
Publication of MX2022014741A publication Critical patent/MX2022014741A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La presente descripción proporciona métodos para determinar si un paciente que exhibe síntomas similares a la tos ferina se beneficiará a partir del tratamiento con agentes terapéuticos que inhiban Bordetella holmesii. Estos métodos se basan en la detección de Bordetella pertussis, Bordetella parapertussis y Bordetella holmesii en una muestra biológica por medio del ensayo para determinar la presencia de los elementos de repetición objetivo de IS481, IS1001 y hIS1001, respectivamente. También se proporcionan los kits para utilizarse en la práctica de los métodos.
MX2022014741A 2016-03-24 2018-09-24 Metodos para detectar bordetella. MX2022014741A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662312883P 2016-03-24 2016-03-24

Publications (1)

Publication Number Publication Date
MX2022014741A true MX2022014741A (es) 2023-01-11

Family

ID=59899804

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018011625A MX2018011625A (es) 2016-03-24 2017-03-23 Metodos para detectar bordetella.
MX2022014741A MX2022014741A (es) 2016-03-24 2018-09-24 Metodos para detectar bordetella.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2018011625A MX2018011625A (es) 2016-03-24 2017-03-23 Metodos para detectar bordetella.

Country Status (7)

Country Link
US (1) US20190382826A1 (es)
EP (2) EP4144867A1 (es)
CN (1) CN109153699A (es)
BR (1) BR112018069316A2 (es)
CA (1) CA3018843A1 (es)
MX (2) MX2018011625A (es)
WO (1) WO2017165599A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017206687B2 (en) * 2016-01-14 2021-12-23 Jamlet MONASELIDZE Differential scanning microcalorimeter device for detecting disease and monitoring therapeutic efficacy
AU2019350777A1 (en) * 2018-09-27 2021-05-20 Gen-Probe Incorporated Compositions and methods for detecting Bordetella pertussis and Bordetellaparapertussis nucleic acid
BR112021014509A2 (pt) * 2019-01-23 2021-09-28 Glycolysis Biomed Co., Ltd Compostos de beta-lactama ou sais dos mesmos para uso na prevenção de ação prolongada ou tratamento de um transtorno de metabolismo de glicose
CN110468223B (zh) * 2019-09-26 2020-07-31 北京卓诚惠生生物科技股份有限公司 基于dUTP/UNG法的肺炎支原体和鲍特菌属核酸检测的引物、探针、试剂盒及方法
CN113373143A (zh) * 2021-07-13 2021-09-10 国药(武汉)医学实验室有限公司 一种用于副百日咳鲍特菌检测探针、试剂盒及其使用方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2134359A4 (en) * 2007-02-23 2010-06-16 Penn State Res Found USE OF A NONVIRULENT BORDETELLA MUTANT AS LIVING VACCINE VECTOR
US10465252B2 (en) * 2007-10-26 2019-11-05 Quest Diagnostics Investments Incorporated Bordetella detection assay
EP2421969B1 (en) 2009-04-24 2015-10-21 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services Selective detection of bordetella species
MX345557B (es) * 2011-07-06 2017-02-02 Quest Diagnostics Invest Inc Amplificacion y deteccion directa de patogenos virales y bacteriales.
EP2764125B1 (en) * 2011-10-04 2018-02-21 Genera Biosystems Limited Compositions and methods of detecting respiratory pathogens using nucleic acid probes and subsets of beads
US20160326571A1 (en) * 2013-10-31 2016-11-10 Atherotech, Inc. Methods for nucleic acid amplification
WO2016085955A1 (en) * 2014-11-25 2016-06-02 Quest Diagnostics Investments Incorporated Amplification and detection of nucleic acids in a biological sample

Also Published As

Publication number Publication date
CN109153699A (zh) 2019-01-04
BR112018069316A2 (pt) 2019-01-22
EP3442984B1 (en) 2022-08-10
US20190382826A1 (en) 2019-12-19
MX2018011625A (es) 2019-01-10
WO2017165599A1 (en) 2017-09-28
EP3442984A4 (en) 2019-11-06
EP4144867A1 (en) 2023-03-08
EP3442984A1 (en) 2019-02-20
CA3018843A1 (en) 2017-09-28

Similar Documents

Publication Publication Date Title
MX2022014741A (es) Metodos para detectar bordetella.
EA201790716A1 (ru) Использование панелей мутантных генов fgfr для выявления онкологических пациентов, которые будут поддаваться лечению ингибитором fgfr
MX2022014633A (es) Metodos para detectar norovirus.
TW201613637A (en) Methods of treating Alzheimer's Disease
PH12020551683A1 (en) Biomarkers for graft-versus-host disease
WO2012006589A3 (en) Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling
MX2017011486A (es) Métodos de detección y cuantificación de il-13 y sus usos en el diagnóstico y tratamiento de enfermedades asociadas a th2.
MX2023001945A (es) Composiciones y metodos para el cribado de tumores solidos.
EP4417218A3 (en) Methods for determining dpp3 and therapeutic methods
NZ703411A (en) Use of markers in the diagnosis and treatment of prostate cancer
BR112016020053A2 (pt) métodos de previsão da reação de pacientes que sofrem de distúrbio inflamatório, de previsão da capacidade de reação de pacientes, de identificação de pacientes que sofrem de distúrbio inflamatório e de seu tratamento, usos de kit e kits
MX2017013390A (es) Método para el tratamiento de cáncer pulmonar.
MX2019003569A (es) Metodos para tratar el cancer con bavituximab en funcion de niveles de b2 glucoproteina 1 y ensayos de estos.
MX2019005443A (es) Combinacion de un inhibidor de brd4 y un antifolato para la terapia del cancer.
BR112016019740A2 (pt) monitoramento do estado de inflamação
MX2024003382A (es) Composiciones y metodos para detectar el adn tumoral circulante.
MX2021007951A (es) Ensayo multiplexado y metodos de uso del mismo.
EP4268820A3 (en) Combination therapy of c-c chemokine receptor-9 (ccr9) inhibitors and anti-alpha4beta7 integrin blocking antibodies for the treatment of inflammatory bowel disease
CO2020008863A2 (es) Biomarcadores de tolerancia inmunitaria inducida por metotrexato
EP1899726A4 (en) METHODS FOR DIAGNOSING AND TREATING CEREBROVASCULAR EVENTS BASED ON NR2 PEPTIDES
CL2021000251A1 (es) Métodos de identificación de pacientes con posibilidad de beneficiarse de un tratamiento con un inhibidor de la telomerasa
MX2021009281A (es) Metodos de deteccion de legionella.
ES2530866T3 (es) Marcador temprano de proteinuria en pacientes tratados con un tratamiento anti-VEGF
DE602008004556D1 (de) Zusammensetzungen und verfahren zum nachweis von störungen in verbindung mit histamin
MX2018011679A (es) Biomarcadores de proteopatias y usos de los mismos.